Skip to content
OpenCapital
Get started

Icahn Enterprises IEP Pharma — Goodwill Gross

Other segment segments

Automotive
$337M0.0%
Energy
$134M-13.0%
Home Fashion
$24M+9.1%
Food Packaging
$6M0.0%

Other financials

Income statement

See full
Revenue$2.2B+18.2%
Net income-$459.0M-8.8%
EPS (diluted)-$0.71+10.1%

Balance sheet

See full
Cash & equivalents$1.3B-40.5%
Total debt$6.9B-5.9%
Total assets$12.9B-16.5%

Cash flow

See full
Operating cash flow$397.0M+318%
CapEx$114.0M+29.5%
Free cash flow$283.0M+205%

Valuation

See full
Market cap$4.9B+1.6%

Profitability

See full
Gross margin-56.5%—
Net margin-3.4%-1.3pp
FCF margin20%—

Returns & leverage

See full
Return on equity-0.1%—
Debt / equity0.7×—

Where this comes from

Reported directly by Icahn Enterprises in its filing.

Tagged under the XBRL concept us-gaap:GoodwillGross.

The official record: Icahn Enterprises’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Icahn Enterprises's pharma — goodwill gross.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Icahn Enterprises's pharma — goodwill gross?
Icahn Enterprises (IEP) reported pharma — goodwill gross of $13M in Q1 2026.
How has Icahn Enterprises's pharma — goodwill gross changed year-over-year?
Icahn Enterprises's pharma — goodwill gross decreased by 0.0% year-over-year, from $13M to $13M.
What is the long-term trend for Icahn Enterprises's pharma — goodwill gross?
Over 4 years (2021 to 2025), Icahn Enterprises's pharma — goodwill gross has grown at a 0.0% compound annual growth rate (CAGR), from $52M to $52M.
What does pharma — goodwill gross mean?
The total acquisition cost assigned to the pharmaceutical segment that exceeds the fair value of identifiable net assets. It represents the initial premium paid for intangible assets such as brand reputation, intellectual property, and market presence before any accumulated impairment.